Recap: Ultragenyx Pharmaceutical Q2 Earnings
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported its Q2 earnings results on Thursday, July 28, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Ultragenyx Pharmaceutical Q2 EPS $(2.26) Down From $(1.81) YoY, Sales $89.34M Up From $86.97M YoY
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(2.26) per share. This is a 24.86 percent decrease over losses of $(1.81) per share from the same period last year. The company reported $89.34
Daily Biotech Pulse: GSK’s Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion’s Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours:
Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday
Gainers
Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue forecast.
Ultragenyx Shares Tumble On Initial Efficacy Missing Expectations, This Analyst Sees ‘Viable Path Forward”
Earlier today, Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) released updated interim GTX-102 data, including Day 128 assessments from 9 patients. The Overall CGI-C-AS…
Nasdaq Rises More Than 300 Points; Crude Oil Moves Higher
U.S. stocks extended gains toward the end of trading, with the Nasdaq Composite gaining around 3% on Tuesday.
Dow Surges 500 Points; Johnson & Johnson Lowers Guidance
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 500 points on Tuesday.
This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Applied Blockchain, Inc. (NASDAQ: APLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue forecast.
The Daily Biotech Pulse: FDA Tentatively Approves Avadel’s Narcolepsy Drug, European Approval Broadens AstraZeneca’s Enhertu in Breast Cancer, Pharma Giants’ Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: